Article Text

Download PDFPDF

1068 Evaluation of the innate and adaptive immune modulatory properties and anti-tumor activity of CD38-targeted interferon alpha
  1. James F Sampson1,
  2. Hong Zhang2,
  3. Tomoya Hara3,
  4. Dong Mei Zhang1,
  5. Adam J Hinthorne1,
  6. Sabrina C Collins1 and
  7. Michael D Curley1
  1. 1Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USA
  2. 2Bristol Myers Squibb, Lawrenceville, NJ, USA
  3. 3Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Modakafusp alfa is a novel immunocytokine therapy comprising two attenuated interferon alpha (IFNα) moieties fused to a humanized anti-CD38 IgG4 monoclonal antibody. Modakafusp alfa is currently being evaluated in Phase I and II clinical trials in multiple myeloma and in solid tumors.

Methods To better understand the impact of modakafusp alfa on different immune cell subsets in immunocompetent mouse models, we generated a murine surrogate of modakafusp alfa comprising an anti-mouse CD38 murine IgG1 antibody genetically fused to two molecules of mouse attenuated IFNα (hereafter referred to as mCD38-mAtt).

Results Intraperitoneal administration of mCD38-mAtt demonstrated anti-tumor activity in a variety of syngeneic tumor models comprising different tumor immune microenvironments, levels of tumor CD38 expression, and intrinsic sensitivities to IFNα. Follow-on mechanistic studies, which targeted the depletion of specific immune cell subsets, revealed that loss of T cells and natural killer (NK) cells blunted tumor growth inhibition by mCD38-mAtt, indicating that these cells may be key effectors mediating the anti-tumor activity of mCD38-mAtt. In syngeneic tumor models, mCD38-mAtt enhanced NK cell activation in the tumor and selectively reduced the macrophage population, thereby modifying the tumor microenvironment. Treatment with mCD38-mAtt increased the presence and activation of tumor antigen-specific CD8 T cells, which correlated with a reduction in tumor mass.

Conclusions Taken together, these data indicate that mCD38-mAtt acts as an enhancer of both innate and adaptive immunity in immunocompetent mouse models that drives an anti-tumor immune response, independently of tumor CD38 expression.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.